Cispatin (Cisplatin) 50mg/50ml

A qualified oncology team administers it as an intravenous infusion with extensive pre and post treatment hydration to protect kidney function.

Cispatin 50mg/50ml Injection Ingredients and Usage

Cispatin 50mg/50ml Injection contains cisplatin, a platinum coordination compound belonging to the alkylating agent anticancer drug class. Oncologists prescribe it for metastatic testicular tumors, usually combined with other chemotherapy agents.

Cispatin 50mg/50ml Injection also treats metastatic ovarian cancer and advanced bladder cancer. It is frequently combined with radiotherapy for cancers of the head, neck, lungs, and cervix. A specialist experienced in chemotherapy administration must supervise treatment throughout.

How Does Cispatin 50mg/50ml Injection Work?

Cisplatin enters cancer cells and undergoes activation to form reactive platinum complexes. These complexes bind to DNA and create crosslinks between adjacent guanine bases, distorting the DNA structure.

By damaging DNA in this way, Cispatin 50mg/50ml Injection blocks DNA replication and transcription, preventing cancer cells from dividing. This disruption triggers cell death, slowing or stopping tumor growth across the cancers it treats.

Cispatin 50mg/50ml Injection Side Effects

Cispatin 50mg/50ml Injection commonly causes kidney related, blood count, and digestive side effects. Antiemetic premedication and hydration help manage these.

• Low red blood cell, white blood cell, and platelet counts

• Severe nausea and vomiting

• Mouth ulcers

• Pain and discomfort at the injection site

• Fatigue

• Numbness or tingling in hands and feet

• Fever

Warnings

• Cispatin 50mg/50ml Injection can cause significant kidney damage; adequate hydration before and after each dose and regular kidney function monitoring are required.

• The medicine can cause hearing loss, which may be permanent; hearing tests are recommended before and during treatment.

• Cispatin 50mg/50ml Injection can cause severe bone marrow suppression, increasing the risk of infection and bleeding; blood counts must be monitored closely.

• Avoid use in patients with severe kidney disease, significant hearing impairment, or pre-existing severe bone marrow depression.

• Avoid combining with aminoglycoside antibiotics or other nephrotoxic and ototoxic drugs, since this increases the risk of kidney damage and hearing loss.

• Do not use aluminum containing needles or infusion equipment, since aluminum reacts with and inactivates cisplatin.

• Cispatin 50mg/50ml Injection is contraindicated in pregnancy and breastfeeding; effective contraception is required for both men and women during treatment.

Cispatin 50mg/50ml Injection Storage Conditions

Store Cispatin 50mg/50ml Injection between 15°C and 25°C, protected from light. Keep the vial in its original packaging until immediately before use, and avoid refrigeration, since cisplatin can crystallize at cold temperatures. Store this medicine out of reach of children and ensure only trained healthcare staff handle preparation and administration.